Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BioLife Solns: Q3 Earnings Insights

BioLife Solns (NASDAQ:BLFS) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:00 PM. Here’s what…
byBenzinga Insights
November 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

BioLife Solns (NASDAQ:BLFS) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:00 PM.

Here’s what investors need to know about the announcement.

Earnings

BioLife Solns beat estimated earnings by 13.16%, reporting an EPS of $-0.33 versus an estimate of $-0.38.

Revenue was down $7.42 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.04 which was followed by a 28.71% drop in the share price the next day.

Here’s a look at BioLife Solns’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.20 -0.21 -0.17 -0.17
EPS Actual -0.24 -0.27 -0.19 -0.15
Revenue Estimate 43.86M 42.94M 43.28M 42.06M
Revenue Actual 39.51M 37.70M 44.26M 40.75M

To track all earnings releases for BioLife Solns visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

By Jelena Martinovic
February 13, 4:22 PM
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO